See more : Blue Ridge Bankshares, Inc. (BRBS) Income Statement Analysis – Financial Results
Complete financial analysis of Evaxion Biotech A/S (EVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evaxion Biotech A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Warner Bros. Discovery, Inc. (WBD) Income Statement Analysis – Financial Results
- MedPeer,Inc. (6095.T) Income Statement Analysis – Financial Results
- Alpha Metallurgical Resources, Inc. (AMR) Income Statement Analysis – Financial Results
- Wai Yuen Tong Medicine Holdings Limited (0897.HK) Income Statement Analysis – Financial Results
- Dr. Lal PathLabs Limited (LALPATHLAB.NS) Income Statement Analysis – Financial Results
Evaxion Biotech A/S (EVAX)
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.00 | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| Gross Profit | 72.89K | -571.32K | -343.45K | -105.72K | -80.98K | -73.93K |
| Gross Profit Ratio | 99.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.92M | 17.06M | 19.58M | 10.90M | 8.22M | 3.73M |
| General & Administrative | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 15.00K |
| Operating Expenses | 22.25M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Cost & Expenses | 22.27M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Interest Income | 154.00K | 2.83M | 2.04M | 216.00K | 9.00K | 2.00K |
| Interest Expense | 897.00K | 1.51M | 915.00K | 223.00K | 1.22M | 698.00K |
| Depreciation & Amortization | 615.95K | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| EBITDA | -21.40M | -22.58M | -24.17M | -16.46M | -11.90M | -6.18M |
| EBITDA Ratio | -29,319.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.20M | -25.26M | -25.83M | -16.57M | -10.86M | -5.63M |
| Operating Income Ratio | -30,406.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -718.00K | 1.32M | 1.12M | -7.00K | -1.16M | -636.93K |
| Income Before Tax | -22.92M | -23.94M | -24.71M | -16.58M | -12.02M | -6.27M |
| Income Before Tax Ratio | -31,390.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -791.22K | -772.00K | -178.00K | -1.56M | -825.00K | -735.00K |
| Net Income | -22.13M | -23.17M | -24.53M | -15.02M | -11.20M | -5.54M |
| Net Income Ratio | -30,308.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| EPS Diluted | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| Weighted Avg Shares Out | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
| Weighted Avg Shares Out (Dil) | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
Evaxion Announces Closing of $15 Million Public Offering
COPENHAGEN, Denmark, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public...
Evaxion Biotech Announces Pricing of $15 Million Public Offering
COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000...
This AI-enabled biotech stock nearly doubled on Wednesday: here's why
Evaxion Biotech (NASDAQ: EVAX) opened nearly 100% up on Wednesday after announcing an “expanded commitment” to developing novel cancer vaccines. Evaxion Biotech stock is rallying today The tailored vaccines will tap on artificial intelligence to identify tumour antigens known broadly...
Why Is Evaxion Biotech (EVAX) Stock Up 30% Today?
Evaxion Biotech (NASDAQ: EVAX ) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE: MRK ). A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion...
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
COPENHAGEN, Denmark, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces an expanded commitment to developing tailored cancer vaccines by targeting a novel...
Evaxion Announces Completion of ADS Ratio Change
COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed change to its ratio of its American Depositary...
Evaxion Announces Plan to Implement ADS Ratio Change
COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”)...
Evaxion Biotech Announces Closing of Private Placement
COPENHAGEN, Denmark, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of its previously announced private placement (the “Private Placement”) with...
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.
Evaxion Biotech Announces Private Placement Financing
COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce a private placement (the “Private Placement”) financing to raise gross...
Source: https://incomestatements.info
Category: Stock Reports